Marta Ferreira

home / authors / marta-ferreira

Articles

46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study

46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study

Heather McArthur, MD, MPH;Peter A. Fasching;Rebecca Dent, MD;Javier Cortés, MD;Lajos Pusztai, MD, DPhil;Sherko Kuemmel;Carsten Denkert;Yeon Hee Park;Rina Hui;Nadia Harbeck, MD, PhD;Masato Takahashi;Seock-Ah Im;Michael Untch, MD, PhD;Marie-Ange Mouret-Reynier;Theodoros Foukakis;Marta Ferreira;Fatima Cardoso;Yu Ding;Cecilia Pinheiro;Jaime Mejia;Joyce A. O’Shaughnessy;Peter Schmid, MD
May 26th 2025
32 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple- Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study

32 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple- Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study

Peter Schmid, MD;Javier Cortes;Rebecca Dent, MD;Lajos Pusztai, MD, DPhil;Heather McArthur, MD, MPH;Sherko Kümmel;Carsten Denkert;Yeon Hee Park;Rina Hui;Nadia Harbeck, MD, PhD;Masato Takahashi;Theodoros Foukakis;Marie-Ange Mouret-Reynier;Marta Ferreira;Seock-Ah Im;Fatima Cardoso;Yu Ding;Wilbur Pan;Konstantinos Tryfonidis;Joyce O’Shaughnessy, MD
July 7th 2024

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
The safety profile of talquetamab continued to show a lower high-grade infection risk relative to other approved anti-BCMA bispecific antibodies.
Published: June 1st 2025 | Updated: June 4th 2025
Talquetamab Elicits Durable Responses, Survival in R/R Multiple Myeloma